Alto Neuroscience (ANRO) Long-Term Debt Issuances (2024 - 2025)
Alto Neuroscience (ANRO) reported Long-Term Debt Issuances of -$18.9 million for Q3 2025, down 1556.77% on a YoY basis from $1.3 million in Q3 2024, and down 196.19% sequentially from $19.7 million in Q1 2025.
Alto Neuroscience (ANRO) Long-Term Debt Issuances (2024 - 2025) Analysis & Trends
Alto Neuroscience (ANRO) has 2 years of Long-Term Debt Issuances data on file, last reported at -$18.9 million in Q3 2025.
- For the quarter ending Q3 2025, Long-Term Debt Issuances fell 1556.77% year-over-year to -$18.9 million; the trailing twelve-month figure through Mar 2026 stood at -$18.9 million (down 184.97% YoY), and the FY2025 full-year result was $750000.0, changed N/A from the prior year.
- Long-Term Debt Issuances slipped to -$18.9 million in Q3 2025, from $19.7 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $19.7 million in Q1 2025 to a low of -$18.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alto Neuroscience | 869.36 Mn | 869.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -18.94 Mn |
| Sep 30, 2025 | -18.94 Mn |
| Mar 31, 2025 | 19.69 Mn |
| Mar 31, 2025 | 19.69 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.30 Mn |